Ogenix

What Ogenix does

Ogenix (legal entity: Neogenix, LLC dba Ogenix) is a US-based private medical device company headquartered in Beachwood, Ohio, operating in the wound care segment. The company develops and commercializes the EPIFLO® Transdermal Continuous Oxygen Therapy (TCOT) system, a small, silent, disposable oxygen concentrator that delivers nearly 100% oxygen 24/7 directly to chronic and post-surgical wounds via a sterile tube, without requiring tanks, chambers, moving parts, or external power. The device is sold as a 28-day prescription-based unit providing continuous oxygen delivery for up to 15 days per unit, and is indicated for diabetic foot ulcers, venous stasis ulcers, pressure ulcers, surgical wounds, skin grafts, burns, and gangrenous lesions.

The company operates a multi-channel go-to-market combining prescription-led clinician sales, direct outreach to hospitals and long-term care facilities (LTAC, SNF, Acute Rehab), home healthcare distribution, and an adjacent veterinary channel primarily serving equine wound care. Revenue is generated exclusively through hardware sales of the disposable EPIFLO device, with pricing not publicly disclosed. Ogenix's commercial position is supported by a growing body of clinical evidence including a 2017 RCT, the 2023 Driver Study in Ostomy and Wound Management, the 2023 IWGDF guideline recommendation, the ADA Diabetes Care citation, and the 2025 Ogenix Protocol published in JVS-VI.

The company is founder-led (Mel Burk, CEO & Chairman) with 11-50 employees, no disclosed funding rounds or institutional investors, and operates exclusively in the US market. Its regulatory pathway is anchored by FDA registration of an interventional device clinical trial (NCT03746132, EPF-418) evaluating TCOT in lower extremity revascularization. The company's strategic emphasis is on clinical evidence accumulation, multi-setting distribution, and guideline inclusion rather than venture-scale commercial expansion.

Name

Ogenix

Legal name

Neogenix, LLC

Website

https://ogenix.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Ogenix is a US-based medical device company that markets EPIFLO®, a disposable transdermal continuous oxygen therapy device for chronic and post-surgical wound care, serving clinicians, hospitals, long-term care facilities, home health, and veterinary markets.

Ownership category

akta.pro rank

Product category

Wound Care Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Oxygen Therapy Systems (Concentrators, Cylinders, Liquid O2, HFNC) (HLAHAGAD)

Keywords

• Wound care devices
• Oxygen therapy systems
• Transdermal oxygen delivery
• Medical device manufacturer
• Chronic wound treatment

Headquarters

HQ city

Beachwood

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Marketing or Sales, Personnel

Revenue model

1. EPIFLO device sales: Sale of the EPIFLO® Transdermal Continuous Oxygen Therapy device as a 28-day disposable unit. Patients/clinicians must obtain a prescription; product is dispensed per treatment cycle with continuous oxygen delivery up to 15 days per unit.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels7 records

Core offering

Ogenix manufactures and sells the EPIFLO® Transdermal Continuous Oxygen Therapy (TCOT) device, a small, silent, disposable oxygen concentrator that delivers nearly 100% oxygen 24/7 directly to chronic and post-surgical wounds via a sterile tube. The 28-day disposable unit is dispensed by clinician prescription and is indicated for diabetic foot ulcers, venous stasis ulcers, pressure ulcers, surgical wounds, skin grafts, burns, and gangrenous lesions, with a parallel veterinary application.

Product overview

Ogenix is a single-product medical-device company built around its flagship offering, the EPIFLO® Transdermal Continuous Oxygen Therapy (TCOT) system — a small, silent, disposable oxygen concentrator that delivers nearly 100% oxygen 24/7 directly to chronic and post-surgical wounds. The core EPIFLO device is supported by a vertical extension into animal health (EPIFLO® for Veterinarians) and an ecosystem of clinical resources, including a Clinical User's Guide, a peer-reviewed protocol publication (JVS-VI 2025), the sponsor-initiated EPF-418 / NCT03746132 clinical trial, a Literature & Clinical Trials library, recommended wound-supply dressings, and patient nutrition guidance. All offerings revolve around the central EPIFLO device rather than a multi-product software platform.

Differentiator

Problem solved

Functional benefit

Brands

• EPIFLO: EPIFLO® Transdermal Continuous Oxygen Therapy (TCOT) — a small, silent, disposable oxygen concentrator device with a sterile tube that delivers nearly 100% oxygen directly to a wound, marketed for diabetic foot ulcers, venous stasis ulcers, pressure ulcers, surgical wounds, skin grafts, burns and other lesions.

Products and services

• EPIFLO® Transdermal Continuous Oxygen Therapy (TCOT) device The flagship Ogenix product: a small, silent, disposable oxygen concentrator connected by a long sterile tube that delivers nearly 100% oxygen 24/7 directly to a chronic or post-surgical wound. Dispensed via clinician prescription as a 28-day unit, requires no tanks, chambers, or oxygen storage, and attaches to the patient in under 30 seconds. Intended for hospitals, long-term care facilities, clinicians, and home health use.
• EPIFLO® for Animal Health (Veterinary Application) A veterinary application of the EPIFLO® transdermal continuous oxygen therapy device, marketed to provide rapid wound healing in animals (with primary emphasis on equine wound care) and to offer portable, oxygen-tank-independent therapy for animal patients.

Quantifiable outcome

• 90% wound closure vs 55% in subjects 65+ (2017 published RCT)
• +4 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Wix.comcoreTechnology or IntegrationWix is Ogenix's website platform and customer engagement provider. Wix processes personal data on Ogenix's behalf, hosts the site in US and European data centers, complies with EU-US Privacy Shield, and stores contact-form submissions in the Wix 'Contacts' database. Wix also sets essential cookies (bSession, consent-policy, hs, TS*, SSR-caching, svSession, _wix_browser_sess, _wixCIDX, XSRF-TOKEN) used for session, security, and monitoring.
• Google (Google Analytics)coreTechnology or IntegrationGoogle Analytics is used via Wix implementation to track user interaction on ogenix.com, including approximate geographical location, device, internet browser, operating system, and IP address. Sets _ga, _gid, _gat (Performance) cookies. Google is treated as a third-party data processor.
• Smith & Nephew (Allevyn Gentle Border Lite)minorChannel Partner/ Reseller/ DistributorRecommended silicone foam border dressing brand listed on Ogenix's Wound Supplies page as an example of a quality dressing to use alongside EPIFLO® therapy.
• 3M Healthcare (Tegaderm High Performance Foam Dressing)minorChannel Partner/ Reseller/ DistributorRecommended silicone foam border dressing brand listed on Ogenix's Wound Supplies page as an example of a quality dressing to use alongside EPIFLO® therapy.
• WoundReferenceminorOthersExternal clinical resource referenced for Dimora silicone foam dressing product information on the Ogenix Wound Supplies page (https://woundreference.com/app/product?id=dimora-silicone-foam-dressing-with-border-3x3-box).
• ClinicalTrials.gov (National Library of Medicine)coreOthersClinicalTrials.gov hosts the Ogenix-sponsored trial NCT03746132 (Oxygen for Vascular Incisional Healing, Sponsor Neogenix, LLC dba Ogenix), providing resource links via the National Library of Medicine and MedlinePlus.
• IWGDF (International Working Group on the Diabetic Foot)coreStrategic or Co-development PartnerIWGDF's clinical guideline recommends topical oxygen as adjunct therapy for diabetic foot ulcers where standard of care alone has failed — a guideline directly relevant to EPIFLO®. Ogenix cites the guideline (with downloadable PDF) on its News Flash / Clinicians page.

Scale indicators8 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Inotec Inc. (Natrox): Natrox is a portable continuous topical oxygen device for chronic wound healing, directly competing with EPIFLO in diabetic foot ulcer and venous leg ulcer care. Similar portable-form-factor concept and clinical evidence base in chronic-wound indications.
• EO2 Concepts: EO2 Concepts' TransCu O2 is a battery-powered, low-flow continuous oxygen delivery system for chronic wounds, directly comparable to EPIFLO's transdermal continuous oxygen approach. Targets the same chronic-wound clinical population with a similar wearable form factor.
• AOTI Inc. AOTI's Topical Wound Oxygen (TWO2) system is a direct competitor to Ogenix's EPIFLO, delivering cyclical topical oxygen therapy to chronic diabetic foot ulcers and other non-healing wounds via a multi-chamber boot device. Closest like-for-like competitor in the topical-oxygen wound-healing category.

Broad incumbents

• Convatec: Convatec is a global advanced-wound-care company with hydrocolloid, foam, and antimicrobial dressings plus adjacent active-therapy products. Competes for the same hospital and home-health wound-care budget pool as Ogenix.
• 3M Health Care (Solventum): 3M's health-care division (now Solventum) is a major wound-care and post-acute care supplier; its Tegaderm dressings are recommended on Ogenix's wound-supplies page. Massive hospital and post-acute channel overlap with Ogenix's EPIFLO target buyer.
• Sechrist Industries: Sechrist is an established manufacturer of hyperbaric oxygen chambers used for chronic-wound care in hospitals. Represents the dominant incumbent modality that EPIFLO is positioned against on cost, portability, and ease-of-use grounds.
• Smith & Nephew: Global wound-care incumbent with a broad portfolio of advanced wound dressings, NPWT, and adjunctive therapies. Sells into the same hospitals, LTACs, and SNFs as Ogenix and is named on Ogenix's dressing-recommendation page as a wound-supply partner.
• Organogenesis (NuCel / Apligraf): Organogenesis markets Apligraf and other living-cell skin substitutes for diabetic foot ulcers and venous leg ulcers, targeting the same chronic-wound patients as EPIFLO. Established wound-care commercial footprint used to layer in additional therapies over time.

Emerging players

• MiMedx Group: MiMedx commercializes placental tissue allografts (EpiFix, AmnioFix) for chronic wound healing, partially overlapping with EPIFLO in chronic-wound indications and SNF/hospital channels. Different mechanism (biologic grafts) but directly comparable customer and outcome claim.
• OxyBand Technologies: OxyBand develops topical oxygen wound dressings and related delivery technologies, partially overlapping with EPIFLO in mechanism (topical oxygen to wound bed) and indications (chronic wounds). Smaller and earlier-stage, but competes for the same clinician mindshare.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ogenix
• Facebookfacebook.com/Ogenix-100050872067869
• LinkedInlinkedin.com/company/ogenix

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ogenix